We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory sync... Vaxart Inc is a clinical-stage biotechnology company. It focuses on the development of oral recombinant vaccines to protect against a wide range of infectious diseases. The products under its tablet pipeline consist of the treatment of Coronavirus, Norovirus, Seasonal Influenza, RSV(respiratory syncytial virus), and HPV(Human papillomavirus) Therapeutic. It operates in a single segment, which is the discovery and development of oral recombinant protein vaccines. Geographically all the business activity functions through the region of the United States. Show more
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”) today announced that the Compensation Committee of the Board of Directors...
Significant progress made in preparing for a Phase 2b study evaluating Vaxart’s oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...
U.S. index futures are rising in Thursday’s pre-market, with investors awaiting producer inflation data and retail sales, which impact U.S. interest rate projections for the year. At 06:39...
SOUTH SAN FRANCISCO, Calif., March 07, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (NASDAQ: VXRT) today announced it will provide a business update and report financial results for the full year ended...
false 0000072444 0000072444 2024-03-04 2024-03-04 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant...
Michael J. Finney, Ph.D. to Continue as Chairman of the Board of Directors SOUTH SAN FRANCISCO, Calif., March 06, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the “Company” or “Vaxart”...
false 0000072444 0000072444 2024-02-27 2024-02-27 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant...
false 0000072444 0000072444 2024-02-14 2024-02-14 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant...
SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934(Amendment No.: 1)* Name of issuer: Vaxart Inc Title of Class of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.12 | 9.67741935484 | 1.24 | 1.41 | 1.18 | 1544523 | 1.24866287 | CS |
4 | 0.07 | 5.42635658915 | 1.29 | 1.41 | 1.03 | 1517788 | 1.18840753 | CS |
12 | 0.7959 | 141.092004964 | 0.5641 | 1.54 | 0.55 | 2056672 | 1.07292127 | CS |
26 | 0.6386 | 88.5223177156 | 0.7214 | 1.54 | 0.53 | 1340844 | 0.95987047 | CS |
52 | 0.6022 | 79.4668778042 | 0.7578 | 1.59 | 0.53 | 1508199 | 0.93291158 | CS |
156 | -4.58 | -77.1043771044 | 5.94 | 11.108 | 0.53 | 4199128 | 5.98223819 | CS |
260 | -0.51 | -27.2727272727 | 1.87 | 24.9 | 0.2543 | 6561477 | 6.90308378 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions